{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:55:21Z","timestamp":1790902521906,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173743"],"award-info":[{"award-number":["82173743"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272742"],"award-info":[{"award-number":["82272742"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473233"],"award-info":[{"award-number":["82473233"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials Advances"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.bioadv.2026.215158","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:14:55Z","timestamp":1788390895000},"page":"215158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["GSH-responsive nanoparticle drug delivery system for simultaneous blockade of CD73\/A2AR to reverse adenosine-mediated immunosuppression"],"prefix":"10.1016","volume":"190","author":[{"given":"Chuanhao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daozuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peixian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huojun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyuan","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bioadv.2026.215158_bb0005","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41571-021-00564-3","article-title":"Tumour burden and efficacy of immune-checkpoint inhibitors","volume":"19","author":"Dall\u2019Olio","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.bioadv.2026.215158_bb0010","first-page":"3044","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol. (Toronto, Ont.)"},{"issue":"7378","key":"10.1016\/j.bioadv.2026.215158_bb0015","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.bioadv.2026.215158_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21145009","article-title":"Immunotherapies and combination strategies for immuno-oncology","volume":"21","author":"Barbari","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bioadv.2026.215158_bb0025","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13045-024-01581-2","article-title":"Dual blockade immunotherapy targeting PD-1\/PD-L1 and CTLA-4 in lung cancer","volume":"17","author":"Cheng","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.bioadv.2026.215158_bb0030","first-page":"221","article-title":"Clinical correlates of response to anti-PD-1-based therapy in patients with metastatic melanoma","volume":"42","author":"Davis","year":"2019","journal-title":"J. Immunother. (Hagerstown, Md.: 1997)"},{"issue":"11","key":"10.1016\/j.bioadv.2026.215158_bb0035","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1158\/2326-6066.CIR-16-0143","article-title":"Targeted next generation sequencing identifies markers of response to PD-1 blockade","volume":"4","author":"Johnson","year":"2016","journal-title":"Cancer Immunol. Res."},{"issue":"10","key":"10.1016\/j.bioadv.2026.215158_bb0040","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1001\/jamaoncol.2022.3707","article-title":"Association of PD-L1 expression and other variables with benefit from immune checkpoint inhibition in advanced gastroesophageal cancer: systematic review and meta-analysis of 17 phase 3 randomized clinical trials","volume":"8","author":"Yoon","year":"2022","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.bioadv.2026.215158_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/cells11030320","article-title":"Immune checkpoint inhibitors in non-small cell lung cancer: progress, challenges, and prospects","volume":"11","author":"Tang","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.bioadv.2026.215158_bb0050","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12943-024-02179-5","article-title":"Current trends in sensitizing immune checkpoint inhibitors for cancer treatment","volume":"23","author":"Wei","year":"2024","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.bioadv.2026.215158_bb0055","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41591-024-02851-9","article-title":"A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results","volume":"30","author":"Rappaport","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioadv.2026.215158_bb0060","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.2147\/OTT.S326178","article-title":"A novel CD73 inhibitor SHR170008 suppresses adenosine in tumor and enhances anti-tumor activity with PD-1 blockade in a mouse model of breast cancer","volume":"14","author":"Liu","year":"2021","journal-title":"Onco. Targets Ther."},{"issue":"4","key":"10.1016\/j.bioadv.2026.215158_bb0065","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004114","article-title":"Genetic characteristics involving the PD-1\/PD-L1\/L2 and CD73\/A2aR axes and the immunosuppressive microenvironment in DLBCL","volume":"10","author":"Zhang","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"20","key":"10.1016\/j.bioadv.2026.215158_bb0070","doi-asserted-by":"crossref","first-page":"5626","DOI":"10.1158\/1078-0432.CCR-13-0545","article-title":"Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs","volume":"19","author":"Allard","year":"2013","journal-title":"Clin. Cancer Res.: an official journal of the American Association for Cancer Research"},{"issue":"5","key":"10.1016\/j.bioadv.2026.215158_bb0075","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1158\/2326-6066.CIR-14-0211","article-title":"Adenosine receptor 2A blockade increases the efficacy of anti-PD-1 through enhanced antitumor T-cell responses","volume":"3","author":"Beavis","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.bioadv.2026.215158_bb0080","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.csbj.2015.03.008","article-title":"A2aR antagonists: next generation checkpoint blockade for cancer immunotherapy","volume":"13","author":"Leone","year":"2015","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"26","key":"10.1016\/j.bioadv.2026.215158_bb0085","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202303445","article-title":"Oncolytic peptide-nanoplatform drives oncoimmune response and reverses adenosine-induced immunosuppressive tumor microenvironment","volume":"13","author":"Wu","year":"2024","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.bioadv.2026.215158_bb0090","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jconrel.2022.09.029","article-title":"Reshaping hypoxia and silencing CD73 via biomimetic gelatin nanotherapeutics to boost immunotherapy","volume":"351","author":"Yuan","year":"2022","journal-title":"J. Control. Release"},{"issue":"7","key":"10.1016\/j.bioadv.2026.215158_bb0095","doi-asserted-by":"crossref","first-page":"6860","DOI":"10.1021\/acs.jmedchem.4c02151","article-title":"Development of CD73 inhibitors in tumor immunotherapy and opportunities in imaging and combination therapy","volume":"68","author":"Bi","year":"2025","journal-title":"J. Med. Chem."},{"issue":"13","key":"10.1016\/j.bioadv.2026.215158_bb0100","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2021108130","article-title":"ATP and cancer immunosurveillance","volume":"40","author":"Kepp","year":"2021","journal-title":"EMBO J."},{"issue":"1","key":"10.1016\/j.bioadv.2026.215158_bb0105","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12943-023-01733-x","article-title":"CD39\/CD73\/A2AR pathway and cancer immunotherapy","volume":"22","author":"Xia","year":"2023","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.bioadv.2026.215158_bb0110","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11302-012-9349-9","article-title":"Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go?","volume":"9","author":"Kumar","year":"2013","journal-title":"Purinergic Signal"},{"issue":"4","key":"10.1016\/j.bioadv.2026.215158_bb0115","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1158\/0008-5472.CAN-17-2826","article-title":"A2AR adenosine signaling suppresses natural killer cell maturation in the tumor microenvironment","volume":"78","author":"Young","year":"2018","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.bioadv.2026.215158_bb0120","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1084\/jem.20062512","article-title":"Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression","volume":"204","author":"Deaglio","year":"2007","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bioadv.2026.215158_bb0125","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.phrs.2019.04.007","article-title":"Complex regulation of ecto-5\u2032-nucleotidase\/CD73 and A(2A)R-mediated adenosine signaling at neurovascular unit: a link between acute and chronic neuroinflammation","volume":"144","author":"Nedeljkovic","year":"2019","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.bioadv.2026.215158_bb0130","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40425-018-0360-8","article-title":"Targeting adenosine for cancer immunotherapy","volume":"6","author":"Leone","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.bioadv.2026.215158_bb0135","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/JTO.0b013e3181f8a1bd","article-title":"The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer","volume":"6","author":"Bremnes","year":"2011","journal-title":"J. Thorac. Oncol."},{"issue":"14","key":"10.1016\/j.bioadv.2026.215158_bb0140","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1158\/0008-5472.CAN-14-0957","article-title":"Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor","volume":"74","author":"Mittal","year":"2014","journal-title":"Cancer Res."},{"issue":"18","key":"10.1016\/j.bioadv.2026.215158_bb0145","doi-asserted-by":"crossref","first-page":"10433","DOI":"10.1021\/acs.jmedchem.0c01086","article-title":"Orally bioavailable small-molecule CD73 inhibitor (OP-5244) reverses immunosuppression through blockade of adenosine production","volume":"63","author":"Du","year":"2020","journal-title":"J. Med. Chem."},{"issue":"21","key":"10.1016\/j.bioadv.2026.215158_bb0150","doi-asserted-by":"crossref","first-page":"22145","DOI":"10.1021\/acs.jmedchem.5c02153","article-title":"Discovery of ORIC-533, an orally bioavailable CD73 inhibitor that maintains activity in high AMP environments to reverse tumor immunosuppression","volume":"68","author":"Moore","year":"2025","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioadv.2026.215158_bb0155","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1158\/2326-6066.CIR-18-0056","article-title":"A2AR antagonism with CPI-444 induces antitumor responses and augments efficacy to anti-PD-(L)1 and anti-CTLA-4 in preclinical models","volume":"6","author":"Willingham","year":"2018","journal-title":"Cancer Immunol. Res."},{"issue":"3","key":"10.1016\/j.bioadv.2026.215158_bb0160","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ccell.2016.06.025","article-title":"Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses","volume":"30","author":"Young","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioadv.2026.215158_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.116672","article-title":"Discovery and optimization of betulinic acid derivatives as novel potent CD73 inhibitors","volume":"59","author":"Zhang","year":"2022","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioadv.2026.215158_bb0170","article-title":"Discovery of dihydrobetulinic acid as a potent small molecule CD73 inhibitor","volume":"225","author":"Wang","year":"2025","journal-title":"Steroids"},{"key":"10.1016\/j.bioadv.2026.215158_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122469","article-title":"Nanotherapeutics for prostate cancer treatment: a comprehensive review","volume":"305","author":"Hu","year":"2024","journal-title":"Biomaterials"},{"key":"10.1016\/j.bioadv.2026.215158_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.119901","article-title":"Programmable prodrug micelle with size-shrinkage and charge-reversal for chemotherapy-improved IDO immunotherapy","volume":"241","author":"Dai","year":"2020","journal-title":"Biomaterials"},{"issue":"49","key":"10.1016\/j.bioadv.2026.215158_bb0185","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202206765","article-title":"Dual-cascade responsive nanoparticles enhance pancreatic cancer therapy by eliminating tumor-resident intracellular bacteria","volume":"34","author":"Kang","year":"2022","journal-title":"Adv. Mater."},{"issue":"18","key":"10.1016\/j.bioadv.2026.215158_bb0190","doi-asserted-by":"crossref","first-page":"18988","DOI":"10.1021\/acs.jmedchem.5c01003","article-title":"Discovery of novel drug-conjugate molecule ZM484 with dual p53-MDM2 and TOP1 inhibition for the treatment of colorectal cancer","volume":"68","author":"Wang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioadv.2026.215158_bb0195","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.ejmech.2018.12.035","article-title":"Small molecule-drug conjugates: a novel strategy for cancer-targeted treatment","volume":"163","author":"Zhuang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioadv.2026.215158_bb0200","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s43588-024-00699-0","article-title":"The future of machine learning for small-molecule drug discovery will be driven by data","volume":"4","author":"Durant","year":"2024","journal-title":"Nat. Comput. Sci."},{"issue":"2","key":"10.1016\/j.bioadv.2026.215158_bb0205","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jconrel.2010.08.027","article-title":"To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery","volume":"148","author":"Danhier","year":"2010","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.bioadv.2026.215158_bb0210","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.bioadv.2026.215158_bb0215","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2174\/1567201817666200210122340","article-title":"Recent advances in self-assembled nanoparticles for drug delivery","volume":"17","author":"Varma","year":"2020","journal-title":"Curr. Drug Deliv."},{"issue":"6","key":"10.1016\/j.bioadv.2026.215158_bb0220","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202107434","article-title":"Polyprodrug nanomedicines: an emerging paradigm for cancer therapy","volume":"34","author":"Yang","year":"2022","journal-title":"Adv. Mater."},{"issue":"26","key":"10.1016\/j.bioadv.2026.215158_bb0225","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202312169","article-title":"Nanomedicine tumor targeting","volume":"36","author":"Lammers","year":"2024","journal-title":"Adv. Mater."},{"issue":"1","key":"10.1016\/j.bioadv.2026.215158_bb0230","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1158\/1535-7163.MCT-16-0343","article-title":"Optimization of a PEGylated glucuronide-monomethylauristatin E linker for antibody-drug conjugates","volume":"16","author":"Burke","year":"2017","journal-title":"Mol. Cancer Ther."},{"issue":"10","key":"10.1016\/j.bioadv.2026.215158_bb0235","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1021\/jm2002958","article-title":"Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates","volume":"54","author":"Zhao","year":"2011","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioadv.2026.215158_bb0240","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41563-019-0566-2","article-title":"The entry of nanoparticles into solid tumours","volume":"19","author":"Sindhwani","year":"2020","journal-title":"Nat. Mater."}],"container-title":["Biomaterials Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772950826004589?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772950826004589?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:24:36Z","timestamp":1790900676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772950826004589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":48,"alternative-id":["S2772950826004589"],"URL":"https:\/\/doi.org\/10.1016\/j.bioadv.2026.215158","relation":{},"ISSN":["2772-9508"],"issn-type":[{"value":"2772-9508","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GSH-responsive nanoparticle drug delivery system for simultaneous blockade of CD73\/A2AR to reverse adenosine-mediated immunosuppression","name":"articletitle","label":"Article Title"},{"value":"Biomaterials Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioadv.2026.215158","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"215158"}}